Cancer Treatment Reviews
Volume 26, Issue 2 , Pages 91-102 , April 2000

Tumour marker measurements in the diagnosis and monitoring of breast cancer

References 

  1. Statland BE, Winkel P. Neoplasia. In:  Kaplan LA,  Pesc AJ editor. Clinical chemistry: theory, analysis, and correlation: 2nd edition. St Louis: CV Mosby,; 1989;p. 734–735
  2. Sikorska H, Shuster J, Gold P. Clinical applications of carcinoembryonic antigen. Cancer Detect Prevent. 1988;12:321–355
  3. Lahousen M, Stettner H, Pickel H, Urdl W, Purstner P. The predictive value of a combination of tumour markers in monitoring patients with ovarian cancer. Cancer. 1987;60:2228–2232
  4. Go VLW, Zamcheck N. The role of tumor markers in the management of colorectal cancer. Cancer. 1982;50:2618–2623
  5. McNeely MDD. Gastrointestinal function and digestive disease. In:  Kaplan LA,  Pesc AJ editor. Clinical chemistry: theory, analysis, and correlation: 2nd edition. St Louis: CV Mosby,; 1989;p. 411–412
  6. Fletcher RH. Carcinoembryonic antigen. Ann Int Med. 1986;104:66–73
  7. Mughal AW, Hortogagyi GN, Fritsche HA, Buzdar AU, Yap HY, Blumenschein GR. Serial plasma carcinoembryonic antigen measurements during treatment of metastatic breast cancer. JAMA. 1983;249:1881–1886
  8. Williams MR, Turkes A, Pearson D, Twining P, Griffiths K, Blamey RW. The use of serum carcinoembryonic antigen to assess therapeutic response in locally advanced and metastatic breast cancer: a prospective study with external review. Eur J Surg Oncol. 1988;14:417–422
  9. Robertson JFR, Pearson D, Price MR, Selby C, Pearson J, Blamey RW, et al. Prospective assessment of the role of five tumour markers in breast cancer. Cancer Immunol Immunother. 1991;33:403–410
  10. Lokich JJ, Zamcheck N, Lowenstein M. Sequential carcinoembryonic antigen levels in the therapy of metastatic breast cancer. Ann Int Med. 1978;89:902–906
  11. Haagensen DE, Kister SJ, Vandevoorde JP, Gates JB, Smart EK, Hansen HJ, et al. Evaluation of carcinoembryonic antigen as a plasma monitor for human breast carcinoma. Cancer. 1978;42:1512–1519
  12. Doyle PJ, Nicholson RI, Groome GV, Blamey RW. Carcinoembryonic antigen (CEA): its role as a tumour marker in breast cancer. Clin Oncol. 1981;7:53–58
  13. Lee YN. Serial tests of carcinoembryonic antigen in patients with breast cancer. Am J Clin Oncol. 1983;6:287–293
  14. Koldovsky U, Wargalla U, Hilkens J, Taylor-Papadimitrou J, Schnuerch HG, Hilgers J. Reactions of monoclonal antibodies against membranes of human milk fat globules with uterine and cervical epithelia during proliferative and secretory stages. Prot Biol Fluids. 1984;32:239–242
  15. Hayes D, Sekine H, Ohao T, Abe M, Keefe K, Kufe DW. Use of murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients. J Clin Invest. 1985;75:1671–1678
  16. Hayes DF, Zurawski VR, Kufe DW. Comparison of circulating CA15.3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol. 1986;10:1542–1550
  17. Pons-Anicet DMF, Krebs BP, Namer M. Value of CA15.3 in the follow-up of breast cancer patients. Br J Surg. 1987;55:567–569
  18. Todini C, Hayes DF, Gelman R, Henderson IC, Kufe DW. Comparison of CA15.3 and carcinoembryonic antigen in monitoring of the clinical course of patients with metastatic breast cancer. Cancer Res. 1988;48:4107–4112
  19. Robertson JFR, Pearson D, Price MR, Selby C, Badley RA, Pearson J, et al. Assessment of four monoclonal antibodies as serum markers in breast cancer. Eur J Cancer. 1990;26:1127–1132
  20. Colomer R, Ruibal A, Salvador L. Circulating tumour marker levels in advanced breast carcinoma correlate with the extent of metastatic disease. Cancer. 1989;64:1674–1681
  21. Colomer R, Ruibal A, Genolla J, Rubio D, Del Campo JM, Bodi R, et al. Circulating CA15.3 levels in the post surgical follow-up of breast cancer patients and in non-malignant diseases. Breast Cancer Res Treat. 1989;13:123–133
  22. Molina R, Zanon G, Filella X, Moreno F, Jo J, Daniels M, et al. Use of serial carcinoembryonic antigen and CA15.3 assays in detecting relapses in breast cancer patients. Breast Cancer Res Treat. 1995;36:41–48
  23. Van Dalen A. New markers for breast carcinoma-associated antigen in comparison with CA15.3. Anticancer Res. 1996;16:2339–2343
  24. Reddish MA, Helbrecht N, Almeida AF, Madiyalakan R, Suresh MR, Longenecker BM. Epitope mapping of Mab B27.29 within the protein core of the malignant breast carcinoma-associated mucin antigen, MUC1. J Tumor Marker Oncol. 1992;7:19–27
  25. Graves R, Hilgers J, Fritsche H, Hayes D, Robertson JFR. MUC1 mucin assays for monitoring therapy in metastatic breast cancer. The Breast. 1998;7:181–186
  26. Hayes DF, Kiang DT, Korzun A, Tondini C, Wood W, Kufe D. CA15.3 and CEA spikes during chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol. 1988;7:38a
  27. Yasasever V, Camlica H, Karaloglu D, Dalay N. Utility of CA15.3 and CEA in monitoring breast cancer patients with bone metastases: special emphasis on “spiking” phenonomen. Clin Biochem. 1997;30:53–56
  28. Martoni A, Zamagni C, Bellanova B, Zanichelli L, Vecchi F, Cacciari N, et al. CEA, MCA, CA15.3 and CA549 and their combinations in expressing and monitoring metastatic breast cancer: a prospective comparative study. Eur J Cancer. 1995;31A:1615–1621
  29. Garcia MB, Blankenstein MA, van der Wall E, Nortier JWR, Schornagel JH, Thijssen JHH. Comparison of breast cancer mucin (BCM) and CA15.3 in human breast cancer. Breast Cancer Res Treat. 1990;17:69–76
  30. Deprés-Brummer P, Itzhaki M, Bakker PJM, Hoek FJ, Veenhof KHN, de Wit R. The usefulness of CA15.3, mucin-like carcinoma-associated antigen (MCA) and carcinoembryonic antigen in determining the clinical course in patients with metastatic breast cancer. J Cancer Res Clin Oncol. 1995;121:419–422
  31. Price MR. High molecular weight epithelial mucins as markers in breast cancer. Eur J Cancer Clin Oncol. 1988;24:1799–1804
  32. Robertson JFR. The role of serum tumour markers for monitoring therapy in metastatic breast cancer. Ligand Assay. 1996;1:257–262
  33. Robertson JFR, Jaeger W, Syzmendera JJ, Selby C, Coleman R, Howell A, et al. The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers. Eur J Cancer. 1999;35:47–53
  34. Robertson JFR, Pearson D, Price MR, Selby C, Blamey RW, Howell A. Objective measurement of therapeutic response in breast cancer using tumour markers. Br J Cancer. 1991;64:757–763
  35. Dixon AR. Tumour markers – a logical approach to the guidance of therapy in advanced breast cancer?. Doctor of Medicine Thesis, University of Nottingham. 1991;
  36. Dixon AR, Jönrup I, Jackson L, Chan SY, Badley RA, Blamey RW. Serological monitoring of advanced breast cancer treated by systemic cytotoxic using a combination of ESR, CEA, and CA15.3: fact or fiction?. Disease Markers. 1991;9:167–174
  37. Dixon AR, Jackson L, Chan SY, Badley RA, Blamey RW. Continuous chemotherapy in responsive metastatic breast cancer: a role for tumour markers?. Br J Cancer. 1993;68:181–185
  38. Williams MR, Turkes A, Pearson D, Griffiths K, Blamey RW. An objective biochemical assessment of therapeutic response in metastatic breast cancer: a study with external review of clinical data. Br J Cancer. 1990;61:126–132
  39. Coombes RC, Powles TJ, Gazet JC, Ford HT, McKinna A, Abbott Z, et al. Screening for metastases in breast cancer: an assessment of biochemical and physical methods. Cancer. 1981;48:310–315
  40. Lamoreux G, Mandeville R, Poisson R, Legault-Poisson S, Jolicoeur R. Biologic markers in breast cancer: a multiparametric study. 1. Increased serum protein levels. Cancer. 1982;49:502–512
  41. Gion M. Serum markers in breast cancer management. The Breast. 1992;1:173–178
  42. Cantwell B, Fennelly JJ, Jones M. Evaluation of follow-up methods to detect relapse mastectomy in breast cancer patients. Ir J Med Sc. 1982;151:1–5
  43. Safi F, Kohler I, Röttinger E, Beger HG. The value of the tumour marker CA15.3 in diagnosing and monitoring breast cancer. Cancer. 1991;68:574–582
  44. Al-Jarallah MA, Behbehani AE, El-Nass SA, Temim L, Ebraheem AK, Ali MAA, et al. Serum CA-15.3 and CEA patters in postsurgical follow-up, and in monitoring clinical course of metastatic cancer in patients with breast carcinoma. Eur J Surg Oncol. 1993;19:74–79
  45. Jäger W, Krämer S, Palapelas V, Norbert L. Breast cancer and clinical utility of CA15.3 and CEA. Scand J Clin Lab Invest. 1995;55:87–92
  46. Iwase H, Kobayashi S, Itoh Y, Fukuoka H, Kuzushima T, Iwata H, et al. Evaluation of serum tumor markers in patients with advanced or recurrent breast cancer. Breast Cancer Res Treat. 1994;33:83–88
  47. Kleist SV, Bombardieri E, Buraggi G, Gion M, Hertel A, Hör G, et al. Immunodiagnosis of tumours. Eur J Cancer. 1993;29A:1622–1630
  48. Gion M, Mione R, Nascimben O, Valsecchi M, Gatti C, Leon A, et al. The tumour associated antigen CA15.3 in primary breast cancer. Evaluation of 667 cases. Br J Cancer. 1991;63:809–813
  49. O’Hanlon DM, Kerin MJ, Kent PJ, Skehill R, Maher D, Grimes H, et al. A prospective evaluation of CA15.3 in stage I carcinoma of the breast. J Am Coll Surg. 1995;180:210–212
  50. Robertson JFR. Blood tumour markers in breast cancer. Tumour Marker Update. 1998;10:31–37
  51. Geraghty JG, Coveney EC, Sherry F, O’Higgins NJ, Duffy MJ. CA15.3 in patients with locoregional and metastatic breast carcinoma. Cancer. 1992;70:2831–2834
  52. Coveney EC, Geraghty JG, Sherry F, McDermott EW, Fennelly JJ, O’Higgins NJ, et al. The clinical value of CEA and CA15.3 in breast cancer management. Int J Biol Markers. 1995;10:35–41
  53. O’Hanlon DM, Kerin MJ, Kent P, Maher D, Grimes H, Given HF. An evaluation of preoperative CA15.3 measurement in primary breast carcinoma. Br J Cancer. 1995;71:1288–1291
  54. Tomlinson IPM, Whyman A, Barrett JA, Kremer JK. Tumour marker CA15-3: possible uses in the routine management of breast cancer. Eur J Cancer. 1995;31A:899–902
  55. O’Brien DP, Skehill R, Horgan PG, Grimes H, Gough DB, Given HF. CA15.3: a reliable indicator of metastatic bone disease in breast cancer patients. Ann R Coll Surg Engl. 1992;74:9–12
  56. Buffaz PD, Gauchez AS, Caravel JP, Vuillez JP, Cura C, Agnius-Delord C, et al. Can tumour marker assays be a guide in the prescription of bone scan for breast and lung cancers?. Eur J Nu Med. 1999;26:8–11
  57. Eur J Surg Oncol. 1999;25:3–23
  58. Krieger G, Kehl A, Wander HE, Salo AM, Rauschecker HF, Nagel GA. Clinical significance of circulating immune complexes (CIC) in patients with metastatic breast cancer. Int J Cancer. 1983;31:207–211
  59. Van Dalen A, Heering KJ, Barak V, Peretz T, Cremaschi A, Geroni P, et al. Treatment response in metastatic breast cancer: a multicentre study comparing UICC criteria and tumour marker changes. The Breast. 1996;5:82–88
  60. Robertson JFR. Prospective confirmation of a biochemical index for measuring therapeutic efficacy in metastatic breast cancer in a multicentre study. The Breast. 1996;5:372–373
  61. Wojtacki J, Dziewulska-Bokiniec A, Rolka-Stempniewicz G. Usefulness of CA15–3 antigen determination for evaluation of response to second-line chemotherapy in patients with breast cancer: preliminary study. Polskie Archiwum Medycyny Wewnetrznej. 1997;97:343–350
  62. Willsher PC, Beaver J, Blamey RW, Robertson JFR. Serum tissue polypeptide specific antigen (TPS) in breast cancer patients: comparison with CA15.3 and CEA. Anticancer Res. 1995;15:1609–1611
  63. Cheung, K. L. Sadozye, A. H. Chan, S. Y. Blamey, R. W. Evans, A. J. Robertson, J. F. R. The role of blood tumour markers in directing cytotoxic therapy in advanced breast cancer [In preparation].
  64. Hayward JL, Carbone PP, Heuson JC, Kumaoka S, Segaloff A, Rubens RD. Cancer. 1977;39:1289–1293
  65. Brown AL, Middleton G, MacVicar AD, Husband JES. T1 weighted magnetic resonance imaging in breast cancer vertebral metastases: changes on treatment and correlation with response to therapy. Clin Radiol. 1998;53:493–501
  66. J Clin Oncol. 1996;14:2843–2877
  67. Whitlock, J. P. L. Evans, A. J. Jackson, L. Chan, S. Y. Robertson, J. F. R. Imaging of metastatic breast cancer: distribution and radiological assessment of involved sites at presentation [In preparation].
  68. Robertson JFR, Whynes DK, Dixon A, Blamey RW. Potential for cost economics in guiding therapy in patients with metastatic breast cancer. Br J Cancer. 1995;72:174–177
  69. Rosselli Del Turco M, Palli D, Cariddi A, Ciatto S, Pacini P, Distante V. Intensive diagnostic follow-up after treatment of primary breast cancer: a randomized trial. JAMA. 1994;271:1593–1597
  70. JAMA. 1994;271:1587–1592
  71. Palli D, Russo A, Saieva C, Ciatto S, Rosselli Del Turco M, Distante V, et al. Intensive vs clinical follow-up after treatment of primary breast cancer: 10-year update of a randomized trial. JAMA. 1999;281:1586
  72. Lancet. 1992;1:1–15, 71–85
  73. Molina R, Zanón G, Filella X, Moreno F, Jo J, Daniels M, et al. Use of serial carcinoembryonic antigen and CA15.3 assays in detecting relapses in breast cancer patients. Breast Cancer Res Treat. 1995;36:41–48
  74. Molina R, Jo J, Zanon G, Filella X, Farrus B, Muñoz M, et al. Utility of c- erb B2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA15.3. Br J Cancer. 1996;74:1126–1131
  75. Molina R, Gion M. Use of blood tumour markers in the detection of recurrent breast cancer. The Breast. 1998;7:109–187
  76. Jäger W, Merkle E, Lang N. Increasing serum tumour markers as decision criteria for hormone-therapy of metastatic breast cancer. Tumor Biol. 1994;12:60–66
  77. Nicolini A, Anselmi L, Michelassi C, Carpi A. Prolonged survival by “early” salvage treatment of breast cancer patients: a retrospective 6-year study. Br J Cancer. 1997;76:1106–1111
  78. Murray A, Willsher P, Price MR, Dixon AR, Robertson JFR. Evaluation of the IMMULITE BR-MA and CEA assays and comparison with immunoradiometric assays for CA15.3 and CEA in breast cancer. Anticancer Res. 1997;17:1945–1949
  79. Nicolini A, Colombini C, Luciani L, Carpi A, Giuliani L. Evaluation of serum CA15.3 determination with CEA and TPA in the postoperative follow-up of breast cancer patients. Br J Cancer. 1991;64:154–158
  80. Sonoo H, Kuerbayashi J. Serum tumour marker kinetics and the clinical course of patients with advanced breast cancer. Surg Today. 1996;26:250–257
  81. Van Dalen A. TPS in breast cancer – a comparative study with carcinoembryonic antigen and CA15.3. Tumour Biol. 1992;13:10–17
  82. Einarsson R. TPS – a cytokeratin marker for therapy control in breast cancer. Scan J Clin Lab Invest. 1995;55:113–115
  83. Van Dalen A. Is TPS able to assist in decision making in breast cancer? In: Tumour associated antigens, oncogenes, receptors, cytokines in tumour diagnosis and therapy at the beginning of the nineties. 6th Symposium on Tumour Markers, Hamburg,. 1991;
  84. Harris L, Lüftner D, Jager W, Robertson JFR. C- erb B2 in serum of patients with breast cancer. Int J Biol Markers. 1999;14:8–15
  85. Tagliabue E, Ménard S, Robertson JFR, Harris L. C- erb B2 expression in primary breast cancer. Int J Biol Markers. 1999;14:16–26
  86. Lüftner D, Schinabel S, Possinger K. C- erb B2 in serum of patients receiving fractionated paclitaxel chemotherapy. Int J Biol Markers. 1999;14:55–59
  87. Weidner N, Semple JP, Welch WR, Folkman J. Tumour angiogenesis and metastases – correlation in invasive breast carcinoma. N Engl J Med. 1991;324:1–8
  88. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, et al. Tumour angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst. 1992;84:1875–1887
  89. Magennis DP. Angiogenesis: a new prognostic marker for breast cancer. Br J Biomed Sc. 1998;55:214–220
  90. Wu J. Apoptosis and angiogenesis: two promising tumor markers in breast cancer. Anticancer Res. 1996;16:2233–2239
  91. Blomqvist C, Elomaa I, Virkkunen P, Porkka L, Karonen SL, Risteli J. The response evaluation of bone metastases in mammary carcinoma. The value of radiology, scintigraphy and biochemical markers of bone metabolism. Cancer. 1987;60:2907–2912
  92. Blomqvist C, Risteli L, Risteli J, Virkkunen P, Sarna S, Elomaa I. Markers of type I collagen degradation and synthesis in the monitoring of treatment response in bone metastases from breast carcinoma. Br J Cancer. 1996;73:1074–1079
  93. Plebani M, Bernardi D, Zaninotto M, De Paoli M, Secchiero S, Sciacovelli L. New and traditional serum markers of bone metabolism in the detection of skeletal metastases. Clin Biochem. 1996;29:67–72
  94. Tahtela R, Tholix E. Serum concentrations of type I collagen carboxyterminal telopeptide (ICTP) and type I procollagen carboxy- and aminoterminal propeptides (PICP, PINP) as markers of metastatic bone disease in breast cancer. Anticancer Res. 1996;16:2289–2293
  95. Yamamoto I, Miura H, Kigami Y, Yamamura Y, Ohta T, Yuu I, et al. Detection of bone metastases by serial measurement of C-terminal telopeptide of type I collagen in patients with malignancy. Kakuigaku. 1996;33:423–429
  96. Shimozuma K, Sonoo H, Fukunaga M, Ichihara K, Aoyama T, Tanaka K. Biochemical markers of bone turnover in breast cancer patients with bone metastases: a preliminary report. Jpn J Clin Oncol. 1999;29:16–22
  97. Berruti A, Dogliotti L, Gorzegno G, Torta M, Tampellini M, Tucci M, et al. Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases. Clin Chem. 1999;45:1240–1247

PII: S0305-7372(99)90151-2

doi: 10.1053/ctrv.1999.0151

Cancer Treatment Reviews
Volume 26, Issue 2 , Pages 91-102 , April 2000

Article Tools